See more : Centuria Industrial REIT (CIP.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Nabriva Therapeutics plc (NBRV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nabriva Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Haidilao International Holding Ltd. (HDALF) Income Statement Analysis – Financial Results
- Itec Corporation (9964.T) Income Statement Analysis – Financial Results
- Immsi S.p.A. (IMS.MI) Income Statement Analysis – Financial Results
- AVT Natural Products Limited (AVTNPL.BO) Income Statement Analysis – Financial Results
- FedNat Holding Company (FNHC) Income Statement Analysis – Financial Results
Nabriva Therapeutics plc (NBRV)
About Nabriva Therapeutics plc
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.67M | 27.22M | 2.86M | 7.75M | 6.50M | 0.00 | 0.00 | 84.00K | 0.00 | 0.00 |
| Cost of Revenue | 28.58M | 13.15M | 766.00K | 70.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.09M | 14.07M | 2.10M | 7.68M | 6.50M | 0.00 | 0.00 | 84.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 19.87% | 51.69% | 73.25% | 99.10% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 14.26M | 12.63M | 15.10M | 26.42M | 82.29M | 49.62M | 47.99M | 22.73M | 8.59M | 10.11M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 41.74M | 29.47M | 13.44M | 7.82M | 3.46M | 3.91M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 45.26M | 51.65M | 55.29M | 62.49M | 41.74M | 29.47M | 13.44M | 7.82M | 3.46M | 3.91M |
| Other Expenses | -1.27M | -1.68M | -2.16M | -1.73M | -272.00K | 492.00K | 55.00K | 2.86M | 77.82K | 34.30M |
| Operating Expenses | 58.26M | 62.60M | 68.22M | 87.17M | 120.88M | 73.77M | 55.05M | 26.84M | 9.89M | 6.74M |
| Cost & Expenses | 86.84M | 75.74M | 68.99M | 87.24M | 120.88M | 73.77M | 55.05M | 26.84M | 9.89M | 6.74M |
| Interest Income | 0.00 | 0.00 | 86.00K | 255.00K | 49.00K | 318.00K | 343.00K | 6.74M | 2.43K | 307.93K |
| Interest Expense | 698.00K | 0.00 | 1.74M | 3.64M | 133.00K | 43.00K | 75.00K | 14.59M | 6.98M | 5.55M |
| Depreciation & Amortization | -3.53M | 637.00K | 1.27M | 470.00K | 510.00K | 432.00K | 233.00K | 150.88K | 152.00K | 197.46K |
| EBITDA | -54.70M | -48.53M | -64.85M | -79.02M | -114.09M | -72.53M | -54.42M | -17.24M | -9.75M | 28.06M |
| EBITDA Ratio | -153.36% | -178.31% | -2,264.42% | -1,019.86% | -1,755.20% | 0.00% | 0.00% | -20,518.94% | 0.00% | 0.00% |
| Operating Income | -51.17M | -48.53M | -66.13M | -79.49M | -114.38M | -73.77M | -55.05M | -23.98M | -9.77M | 22.31M |
| Operating Income Ratio | -143.47% | -178.31% | -2,308.87% | -1,025.93% | -1,759.62% | 0.00% | 0.00% | -28,544.30% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.44M | -432.00K | -3.22M | -3.17M | -356.00K | 767.00K | -515.00K | 2.86M | -6.42M | -5.76M |
| Income Before Tax | -55.62M | -48.96M | -69.35M | -82.66M | -114.73M | -73.00M | -55.56M | -31.82M | -16.18M | 16.55M |
| Income Before Tax Ratio | -155.93% | -179.89% | -2,421.26% | -1,066.89% | -1,765.09% | 0.00% | 0.00% | -37,886.83% | 0.00% | 0.00% |
| Income Tax Expense | 1.57M | 490.00K | 139.00K | 101.00K | 49.00K | 1.36M | -672.00K | -438.41K | 87.55K | 1.07M |
| Net Income | -57.19M | -49.45M | -69.48M | -82.76M | -114.78M | -74.36M | -54.89M | -31.39M | -16.27M | 15.48M |
| Net Income Ratio | -160.33% | -181.69% | -2,426.12% | -1,068.20% | -1,765.85% | 0.00% | 0.00% | -37,364.91% | 0.00% | 0.00% |
| EPS | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 | -623.15 | -638.90 | -741.38 | -149.52 | 142.25 |
| EPS Diluted | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 | -623.15 | -638.90 | -741.38 | -149.52 | 130.92 |
| Weighted Avg Shares Out | 2.68M | 1.73M | 513.80K | 296.80K | 203.18K | 119.32K | 85.91K | 42.34K | 108.82K | 108.82K |
| Weighted Avg Shares Out (Dil) | 2.68M | 1.73M | 513.80K | 296.80K | 203.18K | 119.32K | 85.91K | 42.34K | 108.82K | 108.82K |
7 Stocks to Sell as Banks Melt Down
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
Nabriva's stock is up after sharing antibiotic news
Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
What Is Going on With Nabriva Therapeutics (NBRV) Stock Today?
Buying Penny Stocks Today? What You Need to Know
Nabriva Therapeutics (NBRV) Stock: 1-For-25 Reverse Stock Split Announced
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy
Source: https://incomestatements.info
Category: Stock Reports